http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI1015716-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_285d584b6056fe1a52cfb32091e8d23a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_593a0b1feab1bb70a699e16056db8131
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D219-10
filingDate 2010-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fdf0e5f9d7a30310f7cba62dd4e311b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28ff441eb1120f9d58091fe3a3fc13e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf70be67773bde98c9dac6c757a9dc98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_032d606cd67ebeea5b69bf0d22644629
publicationDate 2015-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber BR-PI1015716-A2
titleOfInvention Testosterone chemotherapy antitumor compounds
abstract Testosterone-chemotherapeutic antitumor compounds. The present invention may be used as an antitumor medicine for testosterone dependent tumors, in particular prostate cancer. The invention is a molecular compound consisting of testosterone molecules chemically linked to chemotherapeutic molecules by means of three or more carbon alkyl molecular spacers for the purpose of combating testosterone-dependent tumors, in particular prostate cancer, eliminating the unwanted effect. of efflux tumor resistance of known chemotherapeutic compounds. The main contribution of the invention is the use of testosterone as a carrier of chemotherapy. In particular, a testosterone molecule chemically linked to a 9-aminoacridine molecule is used by means of an alkyl molecular spacer of three or more carbons to exemplify one of the possible compounds of the present invention.
priorityDate 2010-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414144546
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154496932
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID657181
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID56069
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16132914
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559581
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506651
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4493
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433322774
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5311128
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419554262
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID408786858
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID676246
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7019
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419515371
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416057873
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6013
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419551197
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID413823327
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419590905
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID72879
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419486648
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419536059
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3397
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419524037
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411322314
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID297
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP27429
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393345
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2179
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5281243

Total number of triples: 47.